This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Can Restaurant Stocks Move Higher?
by Sejuti Banerjea
Restaurant companies have been done a lot of innovating this year and they should do much better next year as pandemic concerns wane.
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
Markets Hit Record Highs, Promise Further Growth: 5 Top Picks
by Zacks Equity Research
Promising vaccine news and hopes of further fiscal stimulus helped benchmark indexes to close at record highs, making this a prudent time to invest in names like Cabot (CBT) and Forestar (FOR)
6 S&P 500 Must-Buy Stocks for 2021 Flying High Amid Pandemic
by Nalak Das
It will be prudent to invest in Zacks top-Ranked S&P 500 stocks that have skyrocketed year to date with strong potential for 2021. These include DE, HOLX, LB, PKI, IPGP, QRVO.
Holiday Shopping Shifts to E-Commerce: ETFs to Tap
by Sweta Killa
Given the digital shopping boom, stocks in the Internet and e-commerce retail space look poised for solid gains this holiday season.
Stock Market News for Dec 4, 2020
by Zacks Equity Research
U.S. stock markets closed modestly higher on Thursday after falling from record intraday highs.
J&J (JNJ) Files BLA for Lung Cancer Candidate Amivantamab
by Zacks Equity Research
J&J (JNJ) files a BLA to the FDA for amivantamab for the treatment metastatic non-small cell lung cancer with EGFR Exon 20 insertion mutations.
3 Growth Stocks to Tap the COVID-Driven Shift in MedTech
by Urmimala Biswas
To beat the pandemic blues and maximize capital gains, investors can now scoop up these fundamentally-strong MedTech growth stocks.
Pharma Stock Roundup: Approval of PFE/BNTX Coronavirus Vaccine in UK, Other Updates
by Kinjel Shah
Pfizer (PFE) COVID-19 vaccine gets approval for emergency use in the United Kingdom while Roche's (RHHBY) Xolair gets FDA nod for new indication.
5 Mid-Cap Stocks That Became Top Large Caps Amid Pandemic
by Nalak Das
We have narrowed our search to five mid-cap stocks that have become large caps during the coronavirus hit past eight and a half months. These are: SAM, LB, PKI, UI, GNRC.
Top Analyst Reports for Cisco, CVS Health & Moderna
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), CVS Health Corporation (CVS) and Moderna, Inc. (MRNA).
The Vaccines Are Here. Are We Out of the Woods Now?
by John Blank
It almost seems like we are just an appointment at the doctor's office away from opening up our economy again.
Pfizer (PFE) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Pfizer (PFE) closed at $40.09, marking a -1.74% move from the previous day.
Goldman Sachs, Hexcel Corp, Pfizer, CrowdStrike and Snowflake highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Goldman Sachs, Hexcel Corp, Pfizer, CrowdStrike and Snowflake highlighted as Zacks Bull and Bear of the Day
Stock Market News for Dec 3, 2020
by Zacks Equity Research
U.S. stock markets closed modestly higher on Wednesday as investors await fresh round of fiscal stimulus.
Stocks to Track in December as Markets Peak
by Sweta Killa
December is likely to be filled with events or stock/sector specific news that could provide a boost to the stocks.
3 Biotech Stocks to Buy on First Vaccine Approval Optimism
by Zacks Equity Research
Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors. It will also help biotechs progress with their clinical studies without any disruption.
5 Stocks to Buy at Deep Discount for a Stronger Portfolio
by Nalak Das
Discounted stock price and a favorable Zacks Rank will be the right combination to strengthen one's portfolio in the near future. These stocks include PHM, LEN, SAM, W, DT.
Oil Ends Higher on Vaccine News Despite EIA's Bearish Report
by Nilanjan Choudhury
The top five gainers of the S&P 500 in November were all energy firms - Occidental Petroleum (OXY), Devon Energy (DVN), Apache (APA), Diamondback Energy (FANG) and TechnipFMC (FTI).
CrowdStrike (CRWD) Beats, Snowflake (SNOW) Mixed in Q3
by Mark Vickery
Cyberintelligence security firm CrowdStrike surged well ahead of estimates on every metric in its Q3 report, while fledgling enterprise software firm Snowflake missed on its bottom line.
Pfizer's Coronavirus Vaccine Gets a Nod in UK: ETFs to Shine
by Sweta Jaiswal, FRM
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging progress in coronavirus vaccine development.
Biotech Stock Roundup: BIIB & SAGE Alliance, MRNA, BNTX Coronavirus Updates & More
by Zacks Equity Research
Collaborations, and pipeline and regulatory updates take centerstage in the biotech sector as Moderna (MRNA) and BioNTech (BNTX) provide key updates.
After a Historic November, What Awaits ETFs in December?
by Sweta Killa
Let's delve into some of the major events of December and learn how to tap the opportune moments with ETFs.
Pfizer/BioNTech's COVID-19 Vaccine Gets Approval in U.K.
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate becomes the first-ever vaccine to get authorization.
Encouraging News on COVID-19 Vaccine
by Zacks Equity Research
Encouraging News on COVID-19 Vaccine